RxDoctor Payments Data

Maciej Solarewicz, MD

Internal Medicine · Chicago, ILNPI 1093792574

Payments from drug & device makers

$2,094in general payments, 2019–2025

Across 100 payments — averaging $20.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$547
  • Sun Pharmaceutical Industries Inc.$395
  • Teva Pharmaceuticals USA, Inc.$345
  • Sumitomo Pharma America, Inc.$136
  • Acadia Pharmaceuticals Inc$119
  • Sunovion Pharmaceuticals Inc.$107
  • plus $445 from 8 others

What the payments were for

  • Food & beverage$2,094100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,094 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$602,538
Medicare patients
992
Services billed
5,595

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,150$416,487
Invega SustennaPaliperidone Palmitate68$205,600
TrulicityDulaglutide204$164,398
XareltoRivaroxaban307$100,384
OzempicSemaglutide64$66,759
NuedextaDextromethorphan Hbr/Quinidine77$62,132
JardianceEmpagliflozin175$59,523
MyrbetriqMirabegron199$48,061
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$42,706
XifaxanRifaximin24$38,440
NuplazidPimavanserin Tartrate17$32,963
EntrestoSacubitril/Valsartan81$27,589
JanuviaSitagliptin Phosphate75$24,376
Potassium Chloride762$23,151
Atorvastatin Calcium1,307$22,653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$416,4871,150 claims
Lilly USA, LLCTrulicity, Mounjaro$60$178,528217 claims
Novo NordiskOzempic$54$66,75964 claims
Avanir Pharmaceuticals, Inc.Nuedexta$42$62,13277 claims
Boehringer IngelheimJardiance$82$59,523175 claims
Acadia Pharmaceuticals IncNuplazid$119$32,96317 claims
Otsuka America Pharmaceutical, Inc.Rexulti$547$20,72014 claims
Sumitomo Pharma America, Inc.Gemtesa$136$17,36963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →